近日，齐济投资宣布旗下人民币二期基金完成首关募集，募集规模达9亿元人民币。此次首关完成，为齐济后续在医疗健康领域的投资布局打下根 基，也为推动医疗领域创新与突破贡献力量。 在齐济一期基金的投资实践中，团队已成功领导投资了一系列著名企业家、科学家在关键领域和重要市场的创业项目。 持续打造"神枪手"级投资团 队，构建精准投资体系一直是齐济投资的战略重点。 每日｜荐读 论坛： 新一批敲钟人，已在路上 荐读： 重新发现香港：科创时代的新蓝图 榜单： 全国首只AIC产业母基金来了 热文： 投资人"忙疯了" 据悉，齐济二期将继续深度聚焦于全球前沿技术驱动的医疗健康与生命科学领域，锚定具备全球竞争力的源头创新成果进行投资，以差异化策略引领 产业价值创造，推动医疗健康事业的持续进步。 齐济投资主要关注前沿技术驱动的生物制药、医疗器械和体外诊断等领域的优质投资机会，聚焦具备显著优势的细分赛道，重点关注全球医疗市场以 及病患"未满足的需求"，坚持为被投企业赋能和创造协同价值，共同推进医疗创新，为社会创造价值。 来源：齐济投资 ...

Investment Rating - The report does not explicitly provide an investment rating for the multi-cancer early screening industry in China. Core Insights - The multi-cancer early screening industry in China is experiencing significant growth driven by advancements in technology, particularly AI and genetic testing methods. The market is expected to expand due to increasing healthcare demands from an aging population and rising chronic disease prevalence [5][11][13]. Summary by Sections Industry Overview - The report focuses on the multi-cancer early screening industry in China, analyzing market hotspots, segment conditions, and competitive landscape to understand the current development status and market size [3][5]. Demand Environment - China's healthcare system is evolving to address the needs of an aging population, with a notable increase in chronic disease management capabilities. The demand for in vitro diagnostics is rising, supported by enhanced medical resource availability and government-led healthcare initiatives [5][6][9]. Market Size - The market size of China's in vitro diagnostics industry grew from 118.5 billion CNY in 2019 to 241.7 billion CNY in 2023, with a compound annual growth rate (CAGR) of 19.5%. It is projected to reach 444.2 billion CNY by 2028, with a CAGR of 13.0% from 2023 to 2028 [11][13]. Cancer Screening Demand - The multi-cancer early screening industry has substantial demand potential due to the distribution characteristics of cancer types and a large high-risk population. The report highlights the urgent need for low-dose spiral CT screening for lung cancer, which has a significantly higher incidence rate in China compared to global averages [18][21]. Product Approval Landscape - The early screening product landscape is primarily focused on single cancer types, with colorectal cancer being the most prominent. The market faces challenges such as product homogeneity and competition among over 200 manufacturers in the initial screening space [21][29]. Significance of Digestive Tract Screening - Early screening for digestive tract cancers is crucial due to the "window period" from precancerous lesions to late-stage cancer, where early detection can lead to nearly 100% five-year survival rates. The report emphasizes the cost-effectiveness of early diagnosis compared to late-stage treatment [24][25]. Competitive Landscape - The competitive environment in the digestive tract cancer screening market is intense, with significant differences in product performance and technology among manufacturers. The report notes that many companies focus on colorectal cancer screening, leading to a saturated market with limited differentiation [27][29].

证券日报网12月15日讯英诺特在12月9日回答调研者提问时表示，公司主要投资于与公司主营业务协同 性强的方向，具体方向包括但不限于新产品、新技术平台、新检测领域等。公司对相关项目的研判及决 策较为审慎，具体进展情况公司将按照相关监管规则及时履行信息披露义务。 （文章来源：证券日报） ...

2024年1至12月份，透景生命的营业收入构成为：体外诊断行业占比100.0%。 截至发稿，透景生命市值为30亿元。 每经AI快讯，透景生命（SZ 300642，收盘价：18.4元）12月15日晚间发布公告称，上海透景生命科技 股份有限公司的控股子公司武汉康录生物技术股份有限公司于近日取得国家药品监督管理局颁发的1项 医疗器械注册证。产品名称为"产前染色体数目检测试剂盒"。 每经头条（nbdtoutiao）——"一针两千，童颜针年销3亿元"背后：多家关联方注册地"查无此人"，股民 追问"钱呢"！钱氏姐弟几乎"掏空"江苏吴中，公司即将退市 （记者 曾健辉） ...

Core Viewpoint - Antu Biology has achieved a significant breakthrough in gene detection with the approval of its Sikun series gene sequencers, marking a strategic shift from traditional biochemical detection to precision diagnostics [1][3]. Company Developments - Antu Biology's Sikun series gene sequencers (Sikun2000, Sikun1000, Sikun500) received medical device registration certificates from the National Medical Products Administration, allowing them to enter the clinical testing market, with an expected launch in January 2026 [1]. - The company emphasizes that this is its first sequencing instrument registration certificate, which is strategically important for its development [1]. - The Sikun series is fully self-developed and utilizes reversible terminator technology, facilitating a smooth transition for medical institutions while ensuring data quality and reducing labor and time costs [1]. Industry Insights - The gene testing market in China has shown continuous growth, with the market size increasing from 7.2 billion yuan in 2016 to an expected 37.4 billion yuan by 2024, and projected to reach 153.6 billion yuan by 2030, reflecting a compound annual growth rate of 25.8% over the next five years [2]. - The introduction of Antu Biology's three new products increases the total number of gene sequencers in the domestic market to ten, contributing to the upgrade of the domestic sequencing industry and accelerating the process of domestic substitution [2]. - The core components of the three products are entirely self-developed, moving away from the OEM model, which stabilizes the supply chain and enhances cost-effectiveness, while also driving the upgrade of upstream and downstream industries [3].

每经AI快讯，艾德生物（SZ 300685，收盘价：21.55元）12月12日晚间发布公告称，公司于近日收到欧 洲专利局颁发的发明专利证书。专利名称为"一种用于核酸富集捕获的探针及设计方法"。 2024年1至12月份，艾德生物的营业收入构成为：体外诊断行业占比100.0%。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 （记者 贾运可） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，艾德生物市值为84亿元。 ...

每经AI快讯，博拓生物（SH 688767，收盘价：38.78元）12月11日晚间发布公告称，截至2025年12月11 日，于秀萍女士通过集中竞价交易和大宗交易的方式合计减持公司股份约448万股，占公司当前总股本 的3%。本次减持计划实施完毕。 每经头条（nbdtoutiao）——白金信用卡权益大缩水：贵宾厅限次、酒店减量⋯⋯银行吐槽没赚头，"羊 毛党"薅了个寂寞 （记者 王瀚黎） 截至发稿，博拓生物市值为58亿元。 2024年1至12月份，博拓生物的营业收入构成为：体外诊断试纸占比92.91%，其他业务占比7.09%。 ...

Core Viewpoint - The article discusses the challenges faced by Wuhan Aimesen Life Technology Co., Ltd. (Aimesen) as it prepares for its IPO on the Hong Kong Stock Exchange, highlighting its low revenue, significant losses, and the discrepancies between its product claims and regulatory definitions [1][2][14]. Company Overview - Aimesen was founded in 2015 by Zhang Lianglu, a 27-year-old doctor, aiming to focus on cancer early screening through in vitro diagnostics [2][3]. - The company has submitted its IPO application to the Hong Kong Stock Exchange, presenting its business story to the public for the first time [1]. Financial Performance - Aimesen's annual revenue has remained below 10 million yuan, with reported revenues of 623.3 million yuan, 723.8 million yuan, and 651.3 million yuan for 2023, 2024, and the first half of 2025, respectively [3]. - The company has incurred net losses significantly exceeding its revenue, with losses of 67.92 million yuan, 38.63 million yuan, and 13.91 million yuan during the same periods [3]. Market Context - The cancer early screening market has shown promise, with a compound annual growth rate of over 15% in China's tumor molecular testing market [4]. - Aimesen has developed multiple cancer early screening products, with five receiving Class III medical device registration from the National Medical Products Administration [4]. Product Development and Competition - Aimesen's core products include "Aixin Gan" for liver cancer and "Aiguang Le" for urinary tract cancer, but the company faces competition from other products that have been on the market since 2015 [5]. - The revenue contribution from Aimesen's main product, "Aichang Kang," has decreased from 72.3% in 2023 to 21.8% in the first half of 2025, indicating a shift in its revenue structure [6]. Funding and Investment - Aimesen received initial funding from government support and private investors, including a significant investment from A-share listed company Capbio [7][8]. - The company's valuation has increased significantly over the years, reaching approximately 1.2 billion yuan after multiple funding rounds [8][9]. Related Transactions and Financial Relationships - Aimesen has a high level of related party transactions, with significant receivables from related parties, primarily short-term loans to its founder, Zhang Lianglu [10][11]. - Aimesen's largest customer is its own subsidiary, Wuhan Aino Medical Laboratory, which has contributed a substantial portion of its revenue [11]. Regulatory and Market Challenges - Aimesen's products are classified as "auxiliary diagnostic" rather than "screening," which limits their market potential and usage scenarios [14][15]. - The regulatory landscape for cancer screening products is becoming stricter, with new guidelines requiring clinical trials for products aimed at asymptomatic populations [16].

2025年1至6月份，济高发展的营业收入构成为：贸易行业占比50.0%，房地产及租赁占比26.86%，体外 诊断占比23.14%。 截至发稿，济高发展市值为29亿元。 每经头条（nbdtoutiao）——白金信用卡权益大缩水：贵宾厅限次、酒店减量⋯⋯银行吐槽没赚头，"羊 毛党"薅了个寂寞 每经AI快讯，济高发展（SH 600807，收盘价：3.28元）12月10日晚间发布公告称，因工作原因，王成 东先生、贾为先生、吴宝健先生、雷学锋先生分别辞去公司董事长、董事及下属委员会相关职务，杨继 华先生辞去公司董事会秘书职务。 公司于2025年12月10日召开第十一届董事会第二十八次临时会议，同意选举孙英才先生担任公司第十一 届董事会董事长，任期同第十一届董事会；同意提名杨永波先生、郑云国先生、李猛先生、郭继明先生 为公司第十一届董事会非独立董事候选人，任期自股东会审议通过之日起至第十一届董事会届满之日 止；同意聘任杨永波先生为公司总经理，任期自董事会审议通过之日起至公司第十一届董事会届满之日 止；同意聘任郭继明先生为公司董事会秘书，任期自董事会审议通过之日起至公司第十一届董事会届满 之日止。 （记者 贾运可） ...

每经头条（nbdtoutiao）——最新1520元，飞天茅台批价两年跌了43%，经销商躺赢神话破灭，当潮水 退去谁在裸泳？ 每经AI快讯，东方海洋（SZ 002086，最新价：2.5元）12月10日午间发布公告称，公司第八届第二十六 次董事会会议于2025年12月10日以通讯表决方式召开。会议审议了《关于召开公司2025年第二次临时股 东会的议案》等文件。 （记者 王晓波） 2025年1至6月份，东方海洋的营业收入构成为：水产加工业占比73.14%，体外诊断占比10.19%，海水 养殖业占比9.97%，其他业务--租赁及其他占比6.7%。 ...